How do you approach diagnosis and treatment of HLH/MAS following CAR T-cell therapy?
How is this entity distinct from other secondary HLH entities?
2 Answers
Mednet MemberInvited Expert
Hematology · Harvard Medical School
Answered on
I maintain that immune effector cell associated hyperinflammatory syndrome is NOT HLH. Most patients post CAR-T cell therapy fulfill the criteria for HLH even if they don’t have hyperinflammatory syndrome, so it makes diagnosis very challenging. Many patients with this “HLH-like” hyperinflammatory s...
Join for free or sign in to see the full answer
Mednet MemberInvited Expert
Pediatric Hematology/Oncology · University of Toronto
Answered on
In pediatrics, I have always believed that secondary HLH/MAS is the most severe end of the spectrum of hyperinflammatory syndromes and most of the manifestations are due to the release of proinflammatory cytokines (although increased levels of anti-inflammatory IL10 is usually seen as well). The cyt...
Join for free or sign in to see the full answer